Record-high EXPAREL sales driven by volume growth of 7 percent, marking strongest fourth quarter performance in three ...

First patient dosed in REVEAL pivotal trial evaluating TSHA-102 (N=15, aged 6 to <22 years) in Q4 2025, with enrollment ...

Company Achieves Clinical Development Milestones in 2025, Advances Program for Future Scale Up and StudiesAUSTIN, Texas, Jan.

Company Achieves Clinical Development Milestones in 2025, Advances Program for Future Scale Up and Studies AUSTIN, Texas, Jan. 7, 2026 /PRNewswire/ -- Genprex, Inc.

Record-high EXPAREL sales driven by volume growth of 7 percent, marking strongest fourth quarter performance in three years-- BRISBANE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences ...

Detailed price information for Oxford Biomedica Plc (OXBDF) from The Globe and Mail including charting and trades.

Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing ...

Alloy Kore is designed to support the development of software-defined vehicles (SDVs) and positioned as a safety-certified, ...

Novel capsid technology to enable convenient delivery in the doctor’s office of IKAR-003 for intermediate AMD, designed to prevent progression to sight-threatening disease ...

The companies have proposed a strategic partnership in which Ikarovec will continue to develop its IKAR-003 gene therapy using VectorBuilder's tech.

Although the year brought a steady stream of new treatments, tests, and cutting-edge science, experts worry about how ...